<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803179</url>
  </required_header>
  <id_info>
    <org_study_id>900005</org_study_id>
    <nct_id>NCT00803179</nct_id>
  </id_info>
  <brief_title>Growth Hormone Therapy for Wasting in Cystic Fibrosis</brief_title>
  <official_title>Growth Hormone Therapy for Wasting in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that Growth Hormone (GH) will not only target the peripheral tissue to
      stimulate weight and muscle growth which will maximize nutritional potential and improve
      overall quality of life. We theorize that this will occur through a multitude of factors:
      increased appetite, more constructive utilization of caloric intake and decreased catabolic
      signaling. The first aim will address changes in weight and lean body mass following the
      institution of GH therapy in adults with Cystic Fibrosis (CF) related wasting. The second aim
      will measure impact on quality of life of these individuals. Additionally, the third aim will
      monitor effects of GH therapy on diabetes and insulin sensitivity. Finally, the fourth aim
      will observe changes in the subjects underlying diagnosis of CF, specifically lung function,
      muscle strength and inflammatory state.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following is a more detailed description of the aims listed above:

      Specific Aim 1: Measure change in weight in adults with CF related wasting following GH
      therapy.

      1.1) Monitor weight gained or loss from baseline. 1.2) Assess changes in fat free mass from
      baseline by bioelectrical impedence analysis.

      Specific Aim 2: Evaluate overall quality of life (QOL) in adults with CF related wasting
      treated with GH therapy.

      2.1) Perform CF disease-specific and general QOL analysis via CF QOL questionnaires.

      2.2) Monitor compliance with therapy via subject report.

      Specific Aim 3: Monitor impact of GH therapy in relation to CF related diabetes onset or
      control.

      3.1) Measure impact on insulin sensitivity in non-diabetes subjects 3.2) Observe change in
      exogenous insulin requirements and glycemic control in subjects with diabetes.

      Specific Aim 4: Quantify impact of anabolic therapy on manifestations of underlying diagnosis
      associated with CF.

      4.1) Observe changes in lung function from baseline during GH therapy. 4.2) Determine changes
      in overall muscle strength via hand grip and six minute walk.

      4.3) Evaluate changes in serum markers.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment, patients were lost to follow up
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure Change in Weight in Adults With Cystic Fibrosis (CF) Related Wasting Following Growth Hormone (GH) Therapy</measure>
    <time_frame>14 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate Overall Quality of Life (QOL) in Adults With CF Related Wasting Treated With GH Therapy</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Growth Hormone Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutropin Aqueous (AQ):
Initiation treatment for adult males is 0.2mg/d and for women 0.4mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nutropin AQ</intervention_name>
    <description>Based on recommendations from the 2007 GH Deficiency Consensus Workshop on adult GH deficiency, the recommended initiation of treatment for adult males is 0.2mg/d and for women 0.4mg/d, with a titration upwards based on insulin-like growth factor (IGF-1) (product of GH stimulation at target tissues) levels and patient response. IGF-1 will be monitored at the 3,4,5 and 11 month intervals. For subjects under the age of 25 with an open epiphysis of the hand and/or wrist we will treat with the dose of 0.3mg/kg/week. Subjects will be on growth hormone for 8 months with a baseline visit prior to initiation of therapy and a 3 month follow-up visit after stopping therapy.</description>
    <arm_group_label>Growth Hormone Therapy</arm_group_label>
    <other_name>Growth Hormone (GH)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study.

          -  Age &gt; 18 years

          -  Cystic fibrosis, diagnosed by either sweat chloride or genetic testing

          -  Less than 92% ideal body weight based on body mass index (BMI) of 22 for women and 23
             for men

          -  Moderate or better pulmonary function (Forced Expiratory Volume (FEV1) &gt;40% of
             predicted).

          -  Agree to use an effective method of birth control to prevent pregnancy during the
             research study.

        Women should not nurse (breast feed) a baby while on this study because Nutropin AQ may
        enter breast milk and possibly harm the child.

        Exclusion Criteria:

          -  Pregnancy (positive pregnancy test) prior enrollment in the study

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated

          -  Participation in another simultaneous medical investigation or trial

          -  Pediatric patients

          -  Active neoplasm

          -  History of organ transplantation

          -  Prader Willi Syndrome who are severely obese or have severe respiratory impairment

          -  Patients with hepatic impairment resulting in abnormal coagulation studies (&gt;1.5 times
             normal reference range)

          -  Poorly controlled diabetes as determined by a Hemoglobin A1c greater than or equal to
             9.0%.

          -  Individuals with electrocardiogram abnormality or cardiac pacing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Stalvey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unversity of Massachusetts Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Umms/Ummhc</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <results_first_submitted>November 13, 2012</results_first_submitted>
  <results_first_submitted_qc>December 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 15, 2013</results_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Michael Stalvey</investigator_full_name>
    <investigator_title>Study Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>CF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Growth Hormone Therapy</title>
          <description>Nutropin AQ:
Initiation treatment for adult males is 0.2mg/d and for women 0.4mg/d</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Growth Hormone Therapy</title>
          <description>Nutropin AQ:
Initiation treatment for adult males is 0.2mg/d and for women 0.4mg/d</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measure Change in Weight in Adults With Cystic Fibrosis (CF) Related Wasting Following Growth Hormone (GH) Therapy</title>
        <time_frame>14 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Growth Hormone Therapy</title>
            <description>Nutropin Aqueous (AQ):
Initiation treatment for adult males is 0.2mg/d and for women 0.4mg/d</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Change in Weight in Adults With Cystic Fibrosis (CF) Related Wasting Following Growth Hormone (GH) Therapy</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Overall Quality of Life (QOL) in Adults With CF Related Wasting Treated With GH Therapy</title>
        <time_frame>14 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Growth Hormone Therapy</title>
          <description>Nutropin AQ:
Initiation treatment for adult males is 0.2mg/d and for women 0.4mg/d</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Stalvey, MD, Principal Investigator</name_or_title>
      <organization>UMass Medical School</organization>
      <phone>508-856-4280</phone>
      <email>mstalvey@peds.uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

